Reports & eBooks

Drug Pipeline & Clinical Update - November 2023

December 8, 2023

Capital Rx


  • Ten key new approvals, including Ixchiq®, a new vaccine for the Chikungunya virus, and Lilly's Zepbound, for chronic weight management
  • Six new notable expanded indications including Xtandi® for prostate cancer and Orencia® for active psoriatic arthritis
  • One biosimilar approval: Wezlana™, the first biosimilar referencing Stelara®
  • Four notable generic launches
  • Capital Rx's Updated Drug Recall Report: CLICK HERE to review

Capital Rx's Clinical Team closely monitors the drug landscape to provide our clients with timely information on newly FDA-approved medications, as well as products in the pipeline. Read on to review our November 2023 Monthly Drug Update!

Key New Drug Approvals

Omvoh® (mirikizumab) intravenous then subcutaneous

Approval Date: 10/26/2023 - CLICK HERE for the press release

Indication: Moderate to severe active ulcerative colitis

Cost*: $144,000 annually

Key Considerations:

Agamree® (vamorolone) oral suspension

Approval Date: 10/26/2023 - CLICK HERE for the press release

Indication: Duchenne Muscular Dystrophy (DMD)

Cost*: TBD

Key Considerations:

Voquezna® (vonoprazan) tablet

Approval Date: 11/01/2023 - CLICK HERE for the press release

Indication: Erosive esophagitis, erosive GERD, and relief of heartburn

Cost*: $26 per tablet

Key Considerations:

Zituvimet™ (sitagliptin/metformin) tablet

Approval Date: 11/03/2023 - CLICK HERE for the press release

Indication: Type 2 diabetes

Cost*: TBD

Key Considerations:

Zepbound™ (tirzepatide) subcutaneous injection

Approval Date: 11/08/2023 - CLICK HERE for the press release

Indication: Chronic weight management

Cost*: $1,060 per box (4 syringes)

Key Considerations:

Fruzaqla™ (fruquintinib) capsule

Approval Date: 11/08/2023 - CLICK HERE for the press release

Indication: Metastatic colorectal cancer

Cost*: TBD

Key Considerations:

Ixchiq® (chikungunya vaccine, live) intramuscular injection

Approval Date: 11/09/2023 - CLICK HERE for the press release

Indication: Chikungunya

Cost*: TBD

Key Considerations:

Augtyro™ (repotrecitnib) capsule

Approval Date: 11/15/2023 - CLICK HERE for the press release

Indication: Non-small cell lung cancer

Cost*: $29,000 monthly

Key Considerations:

Truqap™ (capivasertib) tablet

Approval Date: 11/16/2023 - CLICK HERE for the press release

Indication: Hormone receptor-positive breast cancer

Cost*: TBD

Key Considerations:

Ogsiveo™ (nirogacestat) tablet

Approval Date: 11/27/2023 - CLICK HERE for the press release

Indication: Desmoid tumors

Cost*: TBD

Key Considerations:

Notable Expanded Indications

Xtandi® (enzalutamide) capsule – expanded to be used for non-metastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis

Vabysmo® (faricimab-svoa) – expanded to be used for the treatment of macular edema following retinal vein occlusion

Cosentyx® (secukinumab) – expanded to be used for the treatment of adults with moderate to severe hidradenitis suppurativa

Idacio® (adalimumab-aacf) – expanded to be used for the treatment of noninfectious intermediate, posterior and panuveitis in adult patients

Orencia® (abatacept) – expanded to be used for the treatment of active psoriatic arthritis to include pediatric patients ≥ 2 years of age

Keytruda® (pembrolizumab) – expanded as an adjuvant treatment with trastuzumab, fluoropyrimidine, and platinum-containing chemotherapy for first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma(bosutinib) – expanded to treat pediatric patients 1 year of age and older with chronic phase Ph+ chronic myelogenous leukemia (CML), newly-diagnosed or resistant or intolerant to prior therapy

Biosimilar Approvals

Wezlana™ (ustekinumab-auub) intravenous infusion/subcutaneous

Approval Date: 10/31/2023 - CLICK HERE for the press release

Indication: Plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis

Additional Information:

Generic Launches

CaroSpir® (spironolactone 25mg/5mL) suspension

Livalo® (pitavastatin 1mg, 2mg, 4mg) tablet

Mitigare® (colchicine 0.6mg) capsule

Forteo® (teriparatide 20mcg) injection

Contact Us if you'd like to learn more about Capital Rx's full-service pharmacy benefit management (PBM) solutions and clinical programs.


* Cost: actual patient out-of-pocket costs may be lower, as the list price does not reflect insurance coverage, co-pay support for eligible patients, or financial assistance from patient support

DOWNLOAD NOWBack to Insights

Sign up for our newsletter!

Get the latest information on JUDI news, webinars, and industry insights through our newsletter. Sign up now!